RIPK1 is aberrantly expressed in multiple B-cell cancers and implicated in the underlying pathogenesis

According to the latest epidemiology of the US, B-cell cancers account for > 3% of all new cancer cases and > 80% of non-Hodgkin lymphomas. However, the disease-modifying small molecular drug suitable for most B-cell cancers is still lacking. RIPK1 (receptor-interacting serine/threonine-protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Baoyu, Li, Jingyu, Wang, Han, Liu, Jianguo, Li, Jiayong, Sun, Fang, Feng, Dong chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353973/
https://www.ncbi.nlm.nih.gov/pubmed/37462822
http://dx.doi.org/10.1007/s12672-023-00725-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353973/
https://www.ncbi.nlm.nih.gov/pubmed/37462822
http://dx.doi.org/10.1007/s12672-023-00725-z

Ejemplares similares